(Q44966169)

7 December 2017

title

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer (English)

1 reference

7 December 2017

1 reference

Jason R Brown

1

1 reference

7 December 2017

Michael P DiGiovanna

2

1 reference

7 December 2017

Brigid Killelea

3

1 reference

7 December 2017

Donald R Lannin

4

1 reference

7 December 2017

David L Rimm

5

1 reference

7 December 2017

publication date

4 November 2013

1 reference

7 December 2017

published in

Laboratory Investigation

1 reference

7 December 2017

volume

94

1 reference

7 December 2017

issue

1

1 reference

7 December 2017

page(s)

98-106

1 reference

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Neo-adjuvant therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Chemosensitivity prediction by transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Proliferation marker Ki-67 in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Automated subcellular localization and quantification of protein expression in tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Automated Analysis of Tissue Microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.128

Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience

21 January 2018

1 reference

12 December 2020

Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.

1 reference

12 December 2020

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

12 December 2020

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

1 reference

12 December 2020

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

12 December 2020

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18

1 reference

12 December 2020

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

12 December 2020

Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial

1 reference

12 December 2020

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

12 December 2020

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

12 December 2020

Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67

1 reference

12 December 2020

Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer

1 reference

12 December 2020

Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes

1 reference

12 December 2020

10.1038/LABINVEST.2013.128

Identifiers

DOI

1 reference

7 December 2017

1 reference